PT - JOURNAL ARTICLE AU - Zhang, Zhao AU - Zhang, Guorong AU - Guo, Meng AU - Tao, Wanyin AU - Liu, Xing-Zi AU - Wei, Haiming AU - Jin, Tengchuan AU - Zhang, Yue-Miao AU - Zhu, Shu TI - Potential role of aberrant mucosal immune response to SARS-CoV-2 in pathogenesis of IgA Nephropathy AID - 10.1101/2020.12.11.20247668 DP - 2020 Jan 01 TA - medRxiv PG - 2020.12.11.20247668 4099 - http://medrxiv.org/content/early/2020/12/11/2020.12.11.20247668.short 4100 - http://medrxiv.org/content/early/2020/12/11/2020.12.11.20247668.full AB - Aberrant mucosal immunity has been suggested to play a pivotal role in pathogenesis of IgA nephropathy (IgAN), the most common form of glomerulonephritis worldwide. The outbreak of severe acute respiratory syndrome coronavirus (SARS-CoV-2), the causal pathogen of coronavirus disease 2019 (COVID-19), has become a global concern. However, whether the mucosal immune response caused by SARS-CoV-2 influences the clinical manifestations of IgAN patients remains unknown. Here we tracked the SARS-CoV-2 anti-receptor binding domain (RBD) antibody levels in a cohort of 88 COVID-19 patients. We found that 52.3% of the COVID-19 patients produced more SARS-CoV-2 anti-RBD IgA than IgG or IgM, and the levels of the IgA were stable during 4-41 days of infection. Among these IgA-dominated COVID-19 patients, we found a severe COVID-19 patient concurrent with IgAN. The renal function of the patient declined presenting with increased serum creatinine during the infection and till 7 months post infection. This patient predominantly produced anti-RBD IgA as well as total IgA in the serum compared to that of healthy controls. The analysis of the IgA-coated microbiota as well as proinflammatory cytokine IL-18, which was mainly produced in the intestine, reveals intestinal inflammation, although no obvious gastrointestinal symptom was reported. The mucosal immune responses in the lung are not evaluated due to the lack of samples from respiratory tract. Collectively, our work highlights the potential adverse effect of the mucosal immune response towards SARS-CoV-2, and additional care should be taken for COVID-19 patients with chronic diseases like IgAN.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a grant from the Strategic Priority Research Program of the Chinese Academy of Sciences (XDB29030101) (SZ), National Key R&D Program of China (2018YFA0508000) (SZ), and National Natural Science Foundation of China (81822021, 91842105, 31770990, 81821001) (SZ).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was reviewed and approved by the Medical Ethical Committee of the First Affiliated Hospital of USTC (approval number: 2020-XG(H)-014) and the First Affiliated Hospital of Anhui Medical University (approval number: Quick-PJ 2020-04-16).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author, [S.Z.], upon reasonable request.